Aligos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Aligos Therapeutics

04/05/2023 22:53

* Aligos Therapeutics Inc  ALGS.OQ  reported a quarterly
adjusted
loss of 53 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 48 cents per share.
    * Revenue rose 5.9% to $2.72 million from a year ago;
analysts
expected zero. 
    * Aligos Therapeutics Inc's reported EPS for the quarter was
a
loss of 53 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aligos Therapeutics Inc shares had risen by 49.9% this
quarter and gained 37.5% so far this year.
    * The company reported a quarterly loss of $22.96 million.
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:53 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.48          -0.53          Missed
 Dec. 31 2022      -0.47          -0.51          Missed
 Sep. 30 2022      -0.58          -0.44          Beat
 Jun. 30 2022      -0.67          -0.47          Beat